Standout Papers

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration 2006 2026 2012 2019 2.7k
  1. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration (2006)
    David M. Brown, Peter K. Kaiser et al. New England Journal of Medicine
  2. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study (2008)
    David M. Brown, Mark Michels et al. Ophthalmology

Immediate Impact

12 by Nobel laureates 3 from Science/Nature 184 standout
Sub-graph 1 of 17

Citing Papers

Age-Related Macular Degeneration
2024 Standout
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
2024 Standout
46 intermediate papers

Works of Mark Michels being referenced

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
2008 Standout
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
2006 Standout

Author Peers

Author Last Decade Papers Cites
Mark Michels 3783 2924 44 661 16 4.0k
Susan Schneider 4157 3055 43 828 31 4.5k
J P Sarks 3426 2391 53 1055 20 3.7k
Jason S. Ehrlich 3104 2574 37 925 35 3.8k
Carol Chung 4442 3416 60 935 19 5.0k
Scott M. Friedman 3161 2568 78 364 47 3.5k
John A. Wells 3351 2783 111 812 48 3.9k
Cynthia R. Stockdale 3117 2647 52 315 17 3.3k
Andreas Weichselberger 3035 2502 17 386 15 3.1k
I H Chisholm 2378 1719 74 505 20 2.6k
Alyson J. Berliner 4312 3306 124 622 37 4.5k

All Works

Loading papers...

Rankless by CCL
2026